In a significant validation of cutting-edge biomedical exploration, three distinguished researchers from the Broad Institute of MIT and Harvard have been recognized by the National Institutes of Health (NIH) for their bold, unconventional approaches to solving some of medicine’s most intractable challenges.
Erin Chen and Sam Peng have been named recipients of the NIH Director’s New Innovator Award, while JT Neal has been granted the NIH Director’s Transformative Research Award. These honors are part of the NIH’s highly competitive High-Risk, High-Reward Research Program, which is designed to fund exceptionally creative projects that have the potential to overturn established scientific paradigms or open entirely new fields of inquiry.
The three Broad scientists are among a select cohort of 58 researchers nationwide receiving a combined total of more than $237 million in funding this cycle. The awards serve as a powerful testament to the Broad Institute’s mission to foster interdisciplinary, high-impact science that bridges the gap between fundamental biological mechanisms and therapeutic application.
The NIH High-Risk, High-Reward Framework
The NIH’s High-Risk, High-Reward program is distinct from traditional grant mechanisms. Rather than funding incremental, low-risk studies with predictable outcomes, the program explicitly seeks out "out-of-the-box" research. The NIH recognizes that the most significant breakthroughs in human health often stem from projects that face substantial obstacles or require entirely new technological foundations.
By supporting Chen, Peng, and Neal, the NIH is signaling its confidence in their ability to redefine the boundaries of immunology, chemical biology, and genomic medicine.
Profiles in Innovation: The 2024 Awardees
Erin Chen: Harnessing the Skin Microbiome
Dr. Erin Chen, who joined the Broad Institute as a core member in 2023, occupies a unique space at the intersection of clinical practice and laboratory research. In addition to her role at the Broad and her position as an assistant professor of biology at MIT, she serves as an attending dermatologist at Massachusetts General Hospital. This clinical grounding informs her research, which focuses on the complex ecosystem of bacteria residing on human skin.
Her New Innovator Award will fund a project aimed at decoding the "language" between skin microbes and the human immune system. Specifically, Chen is investigating how certain commensal bacteria trigger T cell responses that provide protective immunity against pathogens without inducing the collateral damage of inflammation.
"The goal is to understand the rules of engagement," Chen has noted. By mastering how the body distinguishes between beneficial microbes and harmful invaders, her team hopes to develop a new generation of immunotherapies for skin diseases, potentially offering relief to patients who do not respond to existing treatments.
Sam Peng: Visualizing the Molecular Machinery of Signaling
Dr. Sam Peng, who joined the Broad as a core member in 2022, is an assistant professor of chemistry at MIT whose work centers on the physical chemistry of biological systems. His New Innovator Award project represents a leap forward in microscopy and chemical sensing.
Peng is developing novel single-molecule microscopy techniques to observe the inner workings of G-protein-coupled receptors (GPCRs). GPCRs are the largest family of cell-surface receptors in the human body and are the primary targets for a vast array of modern pharmaceuticals, from antihistamines to antidepressants. Despite their clinical importance, the precise mechanical movements of these receptors during signaling remain difficult to visualize in real-time.
"If we can see the movement, we can control the function," Peng’s research suggests. By refining his microscopy techniques to capture these fleeting molecular snapshots, Peng aims to unlock new pathways for drug design, providing a blueprint for therapeutics that are more precise, more effective, and have fewer side effects.
JT Neal: Scaling the Search for Rare Disease Cures
Dr. JT Neal, an institute scientist and director of systems genomics at the Broad, is no stranger to the NIH’s recognition; he previously received the New Innovator Award in 2021. His current Transformative Research Award marks an evolution in his decade-long commitment to functional genomics.
Neal’s project, titled "Encore," aims to solve one of the most pressing issues in modern medicine: the "n-of-1" nature of rare genetic diseases. While thousands of rare diseases have been identified, the pace of drug discovery is far too slow to address them individually. Encore is a massive experimental and computational platform designed for simultaneous drug screening and repurposing.
By testing more than 1.6 million drug-disease combinations against hundreds of disease-associated phenotypes, Neal is attempting to build a high-throughput engine that can identify therapeutic candidates for hundreds of rare conditions in parallel. It is a paradigm-shifting approach that moves away from the "one-disease-one-drug" model toward a systematic, scalable pipeline for orphan diseases.
A Chronology of Scientific Vision
The path to these awards was not overnight. Each researcher brought years of prior discovery to their current projects:
- 2014–2020: JT Neal establishes his career at the Broad, pioneering methods in functional genomics and 3D organoid modeling, which laid the technical foundation for the Encore platform.
- 2021: JT Neal receives his first NIH New Innovator Award, cementing his reputation as a leader in systems biology.
- 2022: Sam Peng joins the Broad faculty, bringing his expertise in chemical physics and single-molecule dynamics to the institute’s chemical biology program.
- 2023: Erin Chen joins the Broad as a core member, integrating her clinical dermatology background with the institute’s deep expertise in immunology.
- 2024: The NIH announces the current cohort of High-Risk, High-Reward winners, highlighting the interdisciplinary nature of the work being done by Chen, Peng, and Neal.
Supporting Data: Why This Research Matters
The clinical and social implications of these projects are profound.
- Immunology: Chronic inflammation, a target of Chen’s research, is a primary driver of aging, autoimmune disorders, and cancer. By learning to modulate the T-cell response via the skin microbiome, we move closer to "precision immunology."
- Pharmacology: GPCRs are involved in roughly 30% to 50% of all currently marketed drugs. Peng’s work could theoretically optimize these drugs by targeting the specific conformational states of receptors, reducing off-target toxicities.
- Rare Disease Genomics: There are over 7,000 known rare diseases, affecting roughly 300 million people globally. Neal’s platform addresses the lack of financial incentive for private industry to develop treatments for these conditions by drastically lowering the cost and time required for discovery.
Implications for the Future of Biomedical Research
The success of these three scientists highlights a broader shift in the biomedical landscape. The traditional "siloed" approach to research—where biologists, chemists, and computational scientists work in isolation—is being replaced by a highly integrated model.
The Broad Institute, with its focus on collaborative, technology-driven science, provides the ideal ecosystem for such ambitious projects. By embedding these researchers in an environment that prioritizes technical infrastructure, the Broad enables them to tackle problems that would be too complex for a single lab or discipline to solve alone.
Furthermore, these awards reflect a growing trend within the NIH to prioritize "data-heavy" science. Whether it is Neal’s computational screening platform or Peng’s high-resolution imaging, the common thread is the move toward massive data generation to inform biological discovery.
Looking Ahead: Challenges and Hurdles
While the NIH funding provides a significant runway, the researchers face considerable hurdles. For Dr. Chen, the challenge lies in the sheer complexity of the human microbiome; translating findings from mouse models or 2D cell cultures to the human patient is notoriously difficult.
For Dr. Peng, the hurdle is technical: building a microscope that can capture transient molecular motions at the single-molecule level requires constant refinement of lasers, sensors, and cooling systems.
For Dr. Neal, the challenge is logistical and computational. Screening 1.6 million drug-disease combinations requires a massive data infrastructure capable of maintaining quality control across thousands of distinct biological phenotypes.
Despite these challenges, the NIH’s investment serves as an insurance policy against the inherent risks of such pioneering work. By providing long-term, stable funding, the NIH allows these scientists to fail, pivot, and iterate—a process essential to genuine innovation.
Conclusion
The recognition of Erin Chen, Sam Peng, and JT Neal by the National Institutes of Health is more than just a celebration of individual excellence; it is a signal of where the future of medicine is heading. Through the integration of microbiology, single-molecule chemistry, and systematic genomics, these researchers are moving toward a future where diseases are not merely managed but understood at their fundamental, molecular, and ecological roots.
As the Broad Institute continues to support these ambitious projects, the global scientific community watches with anticipation. The high-risk nature of this research is precisely what makes it so necessary. By challenging the status quo, these scientists are not just publishing papers; they are building the technological and conceptual foundations for the next century of medical breakthroughs.
About the Author
